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Abstract 
Background: There is a need for accurate and field‑applicable instruments for the evaluation of the quality of anti‑
malarial drugs. The aim of this study was to determine the diagnostic accuracy of the NanoRam®, a handheld Raman 
spectrometer (RS), to identify anti‑malarial drugs.
Methods: In total, 289 anti‑malarial drugs collected in a randomized field survey in Gabon were evaluated. The 
samples were compared with authentic products as supplied by the official manufacturer. To determine the sensitiv‑
ity and specificity of the handheld NanoRam® spectrometer in the identification of anti‑malarial drugs, a two‑gate 
reversed‑flow design was applied. The standards for reporting of diagnostic accuracy studies (STARD) were followed. 
The index test was the handheld RS. The reference test standards were thin layer chromatography and high perfor‑
mance liquid chromatography with ultraviolet photo diode array detection.
Results: The sensitivity [95 % confidence interval (95 % CI)] and specificity of the RS to correctly identify an anti‑
malarial drug were 100 % (95 % CI 94.9–100 %) and 96 % (95 % CI 92.3–99.0 %), respectively. The RS could not differen‑
tiate between different batches of the same product or different manufacturers of the same product. Intra‑observer 
agreement for 289 samples was 100 %. The average time to conduct the RS was 15 s per sample compared to 45 min 
per sample for TLC.
Conclusion: The handheld RS holds promise as an easy‑to‑use, quick and field‑applicable instrument for the evalu‑
ation of quality of anti‑malarial drugs, potentially empowering pharmacists, drug inspectors and medical regulatory 
authorities.
Trial registration NTR4341 (Dutch Trial Registry)
Résumé 
Contexte: Il est nécessaire d’avoir des outils de terrain fiables pour l’évaluation de la qualité des médicaments anti‑
paludiques. Le but de cette étude était de déterminer la précision diagnostique de l’outil NanoRam®, un spectromètre 
Raman portable (RS), pour identifier les principes actifs des antipaludiques.
Méthodes: Au total, 289 médicaments antipaludiques collectés lors d’une enquête aléatoire au Gabon ont été 
évalués. Les échantillons ont été comparés à des produits authentiques, tel que fourni par le fabricant officiel. Afin de 
déterminer la sensibilité et la spécificité du spectromètre NanoRam® portable dans l’identification des médicaments 
antipaludiques, une méthode à ‘flux inversé à deux canaux‘a été appliquée. Les normes pour la présentation des études 
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Background
Poor-quality, falsified (counterfeit), substandard and 
degraded anti-malarial drugs (for definitions see [1]) are 
important impediments to public health. Studies have 
highlighted the magnitude of the problem of poor quality 
anti-malarial drugs [2–8]. According to the latest World 
Health Organization’s (WHO) estimates, released in 
December 2015, there were 214 million cases of malaria 
in 2015 and 438,000 deaths [9]. Early diagnosis and treat-
ment with appropriate anti-malarial drugs are pivotal 
[10]. The WHO recommends artemisinin-based combi-
nation therapy (ACT) for the treatment of uncomplicated 
falciparum malaria [11–13]. Negative consequences 
arise from the use of poor-quality anti-malarial drugs. 
Anti-malarials with low amounts of active pharmaceu-
tical ingredients (APIs) may cause increased morbidity 
and mortality [14]. An estimated 122,350 [interquartile 
range (IQR): 91,577–154,736] under-five malaria deaths 
are associated with the use of poor-quality anti-malarials, 
representing 3.75 % (IQR: 2.81–4.75 %) of all under-five 
deaths in a sample of 39 countries [15]. However, these 
results should be interpreted with caution since there are 
large gaps in data prevalence of poor-quality anti-malar-
ials [3, 16] and in case fatality rates [15]. As well, inad-
equately low concentrations of the APIs in poor-quality 
drugs may result in sub-therapeutic concentrations of 
the drug in patients, which may engender drug resistance 
[17]. Furthermore, the use of poor-quality anti-malar-
ial drugs leads to significant socio-economic losses for 
patients and their kin, health-care systems and pharma-
ceutical industries producing the genuine product [18]. 
Societies can lose confidence in a pharmaceutical brand, 
drugs, pharmacies, and health-care providers [2].
The spread of poor-quality anti-malarial drugs 
increases the need for rapid detection of such medicines 
throughout the supply chain. The paucity of quality 
assurance laboratories in Africa with appropriate ana-
lytical capabilities (in terms of personnel and equipment) 
slows down the fight against poor-quality medicines. 
Several screening methods have been used, or have 
been investigated for use in screening drug quality in 
low-resource settings. The aim of a screening tool in 
drug quality surveys is to minimize the number of anti-
malarial drugs that will undergo reference-standard 
testing in a (resource-limited) laboratory. Furthermore, 
the ideal screening tool should be low-cost, easy-to-use 
(not requiring specialist training), sustainable (espe-
cially in humid and hot climates) and easy and afford-
able to be repaired (locally). Ideally, the integrity of the 
sample should be sustained. Moreover, the total cost of 
identifying a conspicuous sample should be economically 
balanced in relation to the screening survey as a whole. 
Semi-quantitative thin layer chromatography, which was 
further developed by the Global Pharma Health Fund 
(GPHF), “the Minilab®”, has been available since the past 
couple of years [19, 20]. This technique is applicable in 
the field and relatively cheap (approx. 4500€ in 2014) but 
requires training, the use of chemicals, and is labour-
intensive [21]. It can be used to identify the API and can 
therefore be used as a screening tool to detect falsified 
medicines. It is, however, a semi-quantitative method 
and results should, therefore, be confirmed using more 
accurate methods, such as high-performance liquid chro-
matography (HPLC) [1].
Non-invasive (non-destructive) methods as a screen-
ing and identification tool of APIs have recently gained 
more scientific interest [22, 23]. A recent report evalu-
ated the TruScan® Raman device (using inelastic light 
scattering) for testing pharmaceutical products in the 
field to detect falsified and substandard medicines [24]. 
de précision de diagnostic ont été respectées. Le test de l’indice était le spectromètre NanoRam® portable. Les tests 
de référence étaient la chromatographie sur couche mince (TLC) et chromatographie liquide à haute performance 
avec détection à barrette de diodes photo à ultraviolets.
Résultats: La sensibilité [95 % intervalle de confiance (IC 95 %)] et la spécificité de la RS pour identifier correctement 
un médicament antipaludique était de 100 % (IC à 95 % de 94,9 à 100 %) et 96 % (IC à 95 % de 92,3–99,0 %), respec‑
tivement. Le RS ne pouvait pas différencier entre différents lots du même produit ou provenant de différents fabri‑
cants. L’accord intra‑observateur pour 289 échantillons était de 100 %. Le temps moyen pour effectuer la RS était de 
15 secondes par échantillon par rapport à 45 min par échantillon pour la TLC.
Conclusion: Le spectromètre portable Raman est prometteur comme instrument de mesure, facile à utiliser, rapide 
et facilement applicable sur le terrain pour l’évaluation de la qualité des médicaments antipaludiques, facilitant le 
travail des pharmaciens, des inspecteurs de qualité des médicaments et des autorités de réglementation médicale.
Enregistrement de première instance NTR4341 (Dutch Trial Registry)
Keywords: Artemisinin combination therapy (ACT), Central Africa, Counterfeit, Drug quality, Falsified, Field survey, 
Gabon, Malaria, MEDQUARG, NanoRam®, Sensitivity, Specificity, Raman spectroscopy
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Six pharmaceutical products were under investigation, 
including analgesics and antidiarrhoeal medicines. It was 
shown that it could detect falsified drugs, but was not able 
to discriminate between good-quality and sub-standard 
drugs. The possibilities of Raman spectroscopy as a fast 
and reliable screening method for the detection of falsi-
fied artesunate tablets were investigated before, with the 
Renishaw System-1000® spectrometer (Wotton-under-
Edge, UK), connected to a conventional light microscope. 
The method was able to distinguish between genuine and 
falsified artesunate and to identify the composition of the 
falsified tablets [25]. It was demonstrated that the results 
of the Raman spectroscopy method were in agreement 
with those of colourimetric tests and of liquid chroma-
tography-mass spectrometry of artesunate. The present 
study aims to explore the ability of Raman spectroscopy 
(RS) performed by the NanoRam® handheld device to 
identify anti-malarial drugs and to differentiate between 
similar anti-malarial drugs. The diagnostic accuracy (sen-
sitivity and specificity) of RS was determined, compared 
to thin layer chromatography (TLC).
Methods
Anti‑malarial drugs tested
The samples used in this pilot study were collected in a 
randomized field survey of anti-malarial drugs in Gabo-
nese pharmacies [21], following the medicine quality 
assessment reporting guidelines (MEDQUARG) [1]. The 
randomized field survey was registered in advance (Trial 
registration number: NTR4341 [26]). Also, the costs of 
the present study are reported [27] (Additional file  1). 
Scientific clearance for the field survey was obtained from 
the Scientific Review Committee (SRC) of the Centre de 
Recherches de Médicales de Lambaréné (CERMEL), 
Albert Schweitzer Hospital (SRC number: 2013.11). 
The Ethical Committee of CERMEL decided that ethi-
cal approval of the field survey study was not required, 
as the study is a health care quality assurance study, no 
humans having been subjected to observation or inter-
vention. The detailed methods were described earlier 
[21, 26]. In brief, anti-malarial drugs were collected by 
local fieldworkers from randomly selected pharma-
cies. In total 432 samples were collected, of which 289 
were tested in the present study. Not all samples could 
be tested with the handheld Raman spectrometer (RS) 
because no reference standards of all the anti-malarial 
drugs could be obtained from the producing pharmaceu-
tical companies; or the dosage form was not suitable for 
the handheld RS (e.g., capsule instead of tablet or liquid 
form); or no material was left from the collected sample 
(Fig. 1). The following five anti-malarial drugs were eval-
uated: artemether–lumefantrine (AL, n =  150), quinine 
(Q, n  =  40), sulfadoxine–pyrimethamine (SP, n  =  38), 
dihydroartemisinin–piperaquine (DHA–PQ, n  =  32), 
and artesunate-SP (AS–SP, n  =  31). These anti-malar-
ials were produced by multiple pharmaceutical com-
panies (Table  1). For analytical purposes, paracetamol 
(also known as acetaminophen) 500 mg [collected in the 
pharmacy of the Academic Medical Center (AMC)] was 
included since it is readily available and would be useful 
for studying the ability of the handheld RS to differentiate 
between different products.
Reference test: thin‑layer chromatography
Detailed reference test methods have been described 
before [16]. GPHF Minilab® [20] was used to run semi-
quantitative thin-layer chromatography (TLC) and dis-
integration testing to measure the concentration of 
APIs. The samples failing the TLC test were analysed by 
HPLC, for confirmation. The MiniLab® protocols award 
products a ‘pass’ for TLC if 80 % or more of the labelled 
active ingredient(s) is present. For fixed-dose combina-
tions (e.g., AL) and SP, ‘pass’ was awarded only if both 
active ingredients met this standard. TLC is an accepted 
method to assess the quality of drugs [28–30].
Index test
The present study was conducted in June and July 2015 
at the AMC, University of Amsterdam, The Netherlands. 
All the tests were carried out in similar environmental 
conditions of light (±500 Lux), humidity (70 %) and tem-
perature (±21 °C). The index test was conducted by BJV, 
the reference test by BJV and JMG (TLC) and H. Kaur, 
London School of Tropical Medicine and Hygiene, UK 
(HPLC). Inter-observer agreement was calculated for 
the TLC test, but not for the HPLC and index test. The 
researcher conducting the index test was not blinded 
to the outcome of the reference test. The index test and 
reference test are seldom perfect; therefore, the test 
reproducibility was calculated using the kappa, the intra-
observer agreement [31]. All the index tests were con-
ducted in duplicate.
Index test: Raman spectrometry‑technique
Raman spectrometry (inelastic light scattering or 
“Raman scattering”) is a light-scattering process in 
which the sample under examination is irradiated with 
intense monochromatic light; the light scattered from 
the specimen is analysed for frequency shifts (Fig.  2) 
[32]. This technique can be used to observe vibrational, 
rotational, and other low-frequency modes in a mate-
rial [33]. Raman spectrometry is particularly sensitive 
to non-polar bonds (e.g., C–C single or multiple bonds) 
and less sensitive to polar bonds [22]. In chemistry, it 
is frequently used to provide a “fingerprint” by which a 
molecule can be identified [34].
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Index test: equipment
The NanoRam® hand-held RS was used in this study 
(Fig.  3). The device (model: BWS456, Serial Number: 
SAMLNA, manufactured in March 2014) was rented 
from B&W Tek, Inc. 19 Shea Way, Newark, Delaware, 
USA, 19713). The NanoRam® is a hand-held Raman 
instrument for non-destructive identification and veri-
fication of materials such as APIs, excipients, inter-
mediates and finished products (see Additional file  2 
for specifications). The use of the device does not 
require any training, and handling can be managed by 
untrained non-specialist users. An advantage of this 
technique is that it can analyse drugs through trans-
parent containers (blisters), maintaining the integrity 
of the sample. Raman spectroscopy is an approved 
method by the U.S. and European Pharmacopoeia [35], 
as well as the Pharmacopoeia of the People’s Republic 
of China [36].
Index test: factory calibration of the NanoRam®
The device used had been calibrated according to B&W 
Tek, Inc. calibration procedures to a Raman shift accu-
racy of ±4  cm−1. Standard calibration procedures 
included the creation of a calibration set using B&W 
Tek, INc. SCL series Spectral Calibration Lamps (Mer-
cury and Argon) and Polystyrene Calibration Cap. SCL 
100 series Light Sources have a wavelength accuracy of 
±0.1  nm. The spectral line data for Mercury (Hg) and 
Argon (Ar) are referenced in “Wavelength and transi-
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N = 432 
Extra `falsified` drugs
Paracetamol n= 22
Fig. 1 STARD Flow diagram: identification of anti‑malarials. This diagram scheme is found at http://www.consort‑statement.org/flow_test.pdf
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publication of the National Standards Reference System, 
National Institute of Standards and Technology, U.S. 
Department of Commerce [37]. The calibration was con-
ducted on 30-7-2014 and is valid for a year.
Index test: establishment of a spectral reference library
The NanoRam® spectral device includes a library of 110 
API’s. However, no spectral references for anti-malarial 
drugs were provided with the NanoRam. Therefore, the 
spectra of different anti-malarial drugs which are known 
to be of good quality and which exhibit the variation 
(manufacturer, batch, crystal modification, particle size) 
typical of the anti-malarial to be analysed, were created 
using the instrument’s built-in method without modifi-
cation. For each reference spectrum, 20 runs (scans) are 
necessary. This spectrum or signature is used to com-
pare with spectra of other test samples. In this study, 
only samples provided by the producing pharmaceutical 
company were considered as ‘reference samples’. Librar-
ies for different anti-malarial drugs and dosages were cre-
ated (AL, DHA–PQ, Q, AS–SP, SP; for example libraries 
Table 1 Summary of formulations tested with the brand name, dose, dosage form and manufacturer
Pharmaceutical product Generic name and dose Manufacturer or distributor
Arsiquinoforme® Quinine tablet 250 mg Sanofi Aventis
Artediam® Artesunate–amodiaquine tablet 100/300 mg Adams Pharmaceutical (Anhui) Co., Ltd
Artefan® Artemether–lumefantrine tablet 20/120 mg Ajanta Pharma Ltd, India
Artemether–lumefantrine tablet 80/480 mg
Artim® Artemether–lumefantrine tablet 40/240 mg Twight Litaka Pharma Limited Ltd, India
Artiz (Forte)® Artemether–lumefantrine tablet 40/240 mg Alice Pharma Pvt Ltd, India
Artemether–lumefantrine tablet 20/200 mg
Bimalaril® Artemether–lumefantrine tablet 80/480 mg Bengba Pharmaceutical factory, China
Coartem® Artemether–lumefantrine tablet 20/120 mg Novartis Pharma, Netherlands
Co‑artemax® Dihydroartemisinin–piperaquine tablet 40/320 mg GA Pharma, Greece
Cofantrine® Artemether–lumefantrine tablet 20/120 mg EGR Pharma, Luxembourg
Artemether–lumefantrine tablet 80/470 mg
Colart® Artemether–lumefantrine tablet 20/120 mg Glaxo Smith Kline Group
Combimal® SP tablet 500/25 mg Ajanta Pharma Ltd, Mauritius
Darte‑Q® Dihydroartemisinin–piperaquine tablet 40/320 mg Gosun Pharma Corp, China
Duo‑Cotecxin® Dihydroartemisinin–piperaquine tablet 40/320 mg Beijing Holley‑Cotec Pharmaceutical Ltd, China
Falquin® Quinine tablet 300 mg Plethico pharmaceutical Ltd, India
Fansidar® SP tablet 500/25 mg F.Hoffmann La Roche Ltd, Switzerland
Lariam® Mefloquine tablet 250 mg F.Hoffmann La Roche Ltd, Switzerland
Lufanter® Artemether–lumefantrine 20/120 mg Bliss Gvs Pharma Ltd, India
Artemether–lumefantrine tablet 80/480 mg
Lumart® Artemether–lumefantrine tablet 20/120 mg Cipla Ltd, India
Artemether–lumefantrine tablet 40/240 mg
Malacur® Dihydroartemisinin–piperaquine tablet 40/320 mg Elder pharmaceuticals LTD, India
Maloxine® SP tablet 500/25 mg Gracure Pharmaceuticals Ltd, India
Mephaquin® Mefloquine tablet 250 mg Mepha Ltd, Switzerland
Paracetamol Paracetamol tablet 500 mg Actavis/Allergan, Netherlands
P‑Alaxin® Dihydroartemisinin–piperaquine tablet 40/320 mg Bliss Gvs Pharma Ltd, India
Quinimax® Quinine 500 and 125 mg Sanofi Aventis
R‑Lume® Artemether–lumefantrine tablet 80/480 mg Impact Healthcare Pvt Ltd, India
Surquina® Quinine tablet 250 mg Laboratoire Innotech International, France
Fig. 2 Raman spectroscopy technique “inelastic light scattering”
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see Additional file  3). Match-or-fail comparison deci-
sions were performed by the built-in software. Tablets 
(remaining inside the transparent blisters) were placed in 
front of the laser. Raman bands [Wave number (cm−1)] 
can be assigned to corresponding functional groups. The 
Raman characteristic frequencies of organic molecules 
and inorganic compounds have been described elsewhere 
[38–40]. The main outcomes of the test of a sample are a 
‘match or fail’ result. This match-or-fail outcome is based 
on the p value automatically calculated by the handheld 
RS between the comparator (the reference spectrum) and 
the spectra of the sample under investigation.
Study design and statistical methods
Where appropriate, the standards for reporting of diag-
nostic accuracy studies (STARD) were followed [41] 
(Additional file  4). To determine the sensitivity and 
specificity of the handheld device in the identification 
of anti-malarial drugs, a two-gate reversed-flow design 
was applied [42]. The index test (Raman spectroscopy 
performed by the NanoRam® handheld spectrometer) 
and reference standard (thin layer chromatography and 
high performance liquid chromatography with ultra-
violet photo diode array detection) were performed in 
reverse order. Reversing the order in which the index test 
and reference standard are conducted will not change 
the estimates of diagnostic accuracy. This type of design 
was chosen because of practical reasons since the sam-
ples were evaluated in another study already [21], and the 
RS was not yet available in our laboratory. In the pref-
erable one-gate design, cases and controls are sampled 
from the same pool (anti-malarial drug collection); this 
was however not possible due to a lack of ‘cases’ (falsified 
drugs), thus a two-gate design was necessary (see below). 
To achieve sufficient power for the diagnostic accuracy 
calculations, the sample size was calculated as described 
in the sample size methods by Flahault et al. [43]. When 
the prevalence of poor quality drugs is less than 50  %, 
two assumptions ought to be made: the expected speci-
ficity (or sensitivity) values of the new diagnostic test, 
and the minimum acceptable lower confidence limit. For 
the NanoRam®, two studies showed high sensitivity and 
specificity, but exact numbers were not reported [24, 25].
Assuming that the specificity will be high, at the mini-
mal acceptable confidence limit of 0.7 (together with the 
required probability which was set here at 0.95 that this 
limit is not violated), the minimum number of falsified 
or poor-quality samples required is 24 [43]. The preva-
lence of poor-quality drugs in Gabon is 0.5 % [(95 % CI 
0.08–1.84  %) [21]. Using the prevalence of 0.5  %, the 
number of controls would be 199, using the equation 
Ncontrols  =  Ncases  ×  [(1  −  Prevalance)/Prevalence]. 
The controls come from the same pool as the cases, 
thus the definite sample size is 223. Since the reference 
test was already conducted before the index test, it was 
known that only two samples were of poor quality [21]. 
Therefore, 24 − 2 = 22 extra controls were added (“fal-
sified anti-malarial drugs”: in this model paracetamol 
500  mg was used). This two-gate model is an accepted 
design in the early investigation of a new diagnostic 
test [42], it has, however, been criticized for leading to 
inflated estimates of accuracy. Paracetamol was used 
since this product has been sold frequently as being an 
anti-malarial drug in South East Asia [44] and is readily 
available.
Data was analysed using SPSS (Version 21.0, IBM, NY, 
USA). The results of each diagnostic test of every sam-
ple were recorded in Excel and SPSS. The diagnostic 
accuracy was defined by sensitivity and specificity with 
95 % confidence intervals (CIs), which were computed as 
by standard literature [45, 46]. A cross tabulation of the 
index text results by the results of the reference test was 
conducted.
Results
In this study, a total of 289 anti-malarial drugs were 
tested (Fig.  1). The index test was conducted within 
8  months after the reference test. All samples were 
tested while remaining in their transparent blisters, 
except for DHA–PQ tablets (n =  32, 11 %): the blisters 
Fig. 3 The NanoRam® handheld Raman spectrometer
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were transparent but the tablets have a thick blue coat-
ing resulting in a lack of penetration of the laser. These 
tablets were broken into half with a pill splitter, and sub-
sequently tested. On average, a reference spectrum of an 
anti-malarial drug (20 runs) could be created within 3.5 
(min–max: 3–6) minutes. The average time to conduct a 
match/fail analysis for one sample was 15: 10 s of enter-
ing data (name and sample number of the drug under 
investigation) and 5 s for scanning the drug sample and 
obtaining a match/fail result. In comparison, the semi-
quantitative layer chromatography technique used by the 
GPHF MiniLab® costs on average approximately 45 min 
processing time per sample.
Precision test of the NanoRam spectrometer
To investigate the capability of the NanoRam spectrom-
eter to produce reproducible results, a match/fail analysis 
using a reference tablet was compared with the reference 
spectrum of the same sample. All the precision tests were 
conducted under the same circumstances and in dupli-
cate. AL, DHA–PQ, Q, SP, AS–SP and paracetamol were 
utilized in different strengths. Table 2 depicts the results 
of the precision tests, Figs. 4a–d and 5a, b show examples 
of the precision test. Important to note is that the results 
of the match/fail scans are adjusted for the concentra-
tion of API in the tablet. For example, a match/fail test of 
AL 40/240  mg tablet matched the NanoRam’s reference 
spectrum of AL 20/120  mg tablet. In strict sense, this 
should be a “fail”. However, the NanoRam spectrometer 
only measures the concentration of the API in the tablet, 
and does not take into account tablet size or total weight, 
which may differ between different strengths of the same 
drug. In this particular case, the 40/240 mg dosage con-
tained the same concentration of API as the 20/120 mg 
tablet, but the tablet was twice as big.
Diagnostic accuracy of the RS
To investigate the sensitivity and specificity of the device, 
different comparison scenarios to assess the ability of 
the RS to discriminate between different samples were 
evaluated. First, the diagnostic accuracy of the RS to 
correctly identify the API in the anti-malarial drug was 
determined. The 289 anti-malarial drugs plus additional 
fakes (22 paracetamol 500 mg tablets) were analysed with 
the RS. The sensitivity and specificity were 100 % (95 % 
CI 94.9–100 %) and 96.2 % (95 % CI 92.3–99.0 %) respec-
tively (Table  3). The falsified AL sample was correctly 
identified as having no API inside the tablets (Fig. 6). The 
suspected SP sample which failed the TLC test, was dem-
onstrated with HPLC to contain the stated API, but the 
amount was approximately halve of the dose. The API 
was not identified by the NanoRam and thus “failed” the 
test (Fig.  7). However, the device suggested the API SP 
as closely related to the generated spectrum. 11 samples 
of SP “failed” the RS test, but passed the reference test. 
These 11 SP samples failed the RS test again in the subse-
quent round. The device suggested the API SP as closely 
related to the generated spectrum. Difficulty in using 
Raman spectroscopy in identifying SP has been previ-
ously reported [47]. A reason for this is the high fluo-
rescence of SP itself. The 22 paracetamol tablets were all 
correctly identified as being a non-malarial drug.
Comparison of different lots of the same product
AL, Q, SP were used in this test. One batch of AL (Coar-
tem, Novartis, Batch: X1639) was used to generate a 
Raman reference spectrum. This reference spectrum was 
compared to samples of the same batch (X1639), and 35 
samples of 15 selected other batches of the same manu-
facturer Novartis. All samples matched to the compara-
tor batch. For SP and Q, no differences between different 
lots of the same product could be identified.
Comparison of similar products from different 
manufacturers
The capacity of the RS to discriminate between similar 
products from different pharmaceutical companies was 
also investigated (Table  1). The RS could not discrimi-
nate between products with the same API from different 
manufacturers.
Table 2 Precision tests
Sample Number of  
reference samples




Artemether–lumefantrine 20/120, 40/240, 80/480 mg 72 72 100
Quinine sulphate 300 mg 35 35 100




Paracetamol 500 mg 48 48 100
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Fig. 4 Raman spectroscopy precision test results for a artemether lumefantrine 20/120 mg. b Dihydroartemisinin–piperaquine c quinine sulphate 
d sulfadoxine–pyrimethamine
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Discussion
This study represents the first evaluation of the diagnos-
tic accuracy of the NanoRam® spectrometer to iden-
tify and discriminate between anti-malarial drugs. The 
results suggest that the handheld NanoRam® spectrom-
eter has a high sensitivity and specificity to identify anti-
malarial drugs. All falsified anti-malarials were detected 
by the RS. Some samples (n  =  11, only SP) contained 
the stated API, but still failed the test (“false positives”). 
The results suggest that the NanoRam® can be used to 
screen large quantities of anti-malarial drugs in a fast 
and non-destructive way, but caution is required when 
screening SP tablets. Minimal training was required and 
agreement between the tests was 100 %. Reference stand-
ards for the NanoRam® are not provided with the device 
but can be easily created and shared between users 
around the globe.
Strengths and limitations
The major strength of the present study is the large num-
ber of different random collected anti-malarial samples, 
which enabled us to investigate and create different ref-
erence spectra for the anti-malarial drugs. Another 
strength is that the sample size was sufficient to calcu-
late the diagnostic accuracy. A major limitation of this 
study is that the reference standard is a semi-quantitative 
method, and that the sensitivity of the reference method 
is limited [48]. This means that false negatives might 
be present. The probability of false positives has been 
reduced, by analysing the samples failing TLC also with 
HPLC. It was not possible to analyse all samples with 
HPLC because the funds for this study were insufficient 
(HPLC of all samples costs approximately 14,000€). An 
important next step for further research should be an 
Fig. 5 Raman spectroscopy precision test results for a Artesunate‑SP,  b Paracetamol
Table 3 2  ×  2 Table Raman spectroscopy vs. thin-layer 
chromotography
TP true positive, FP false positive, FN false negative, TN true negative, RS Raman 






Fail RS 24 (TP) 11 (FP) 35
Pass RS 0 (FN) 276 (TN) 276
Total 24 287 311
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evaluation of the diagnostic accuracy of the handheld RS 
compared to the reference standard HPLC. Another limi-
tation of our study is that we had a number of missing 
reference samples and had to exclude 143 anti-malarial 
samples. Moreover, the number of ‘true’ falsified anti-
malarials was small, and an extra case group (paraceta-
mol tablets) had to be added, which is a source of bias 
and might have led to an overestimation of the diagnos-
tic accuracy. Another potential source of bias is that the 
investigator could not be blinded for the results of the 
reference test; this risk is minimal because the device 
provides a ‘pass’ or ‘fail’ with a p value, leaving little room 
for interpretation errors. Lastly, a limitation of this study 
is that the ability of the handheld RS device to discrimi-
nate between different dosage strengths as an indicator 
of the quality of anti-malarial drugs was not investigated. 
The number of different samples with different dosages 
for this analysis was insufficient. The ability to differen-
tiate between dosages is important since products with 
reduced APIs have been produced.
The handheld RS (NanoRam®) device is commer-
cially available but expensive. However, it could be 
Fig. 6 Raman spectroscopy of suspected artemether–lumefantrine sample
Fig. 7 Raman spectroscopy of suspected SP sample. Sulphadoxine–pyrimethamine suspected sample containing only have the dose
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cost-effective to have a device as a medicine regulatory 
authorities since it can reduce the number of products 
that will undergo reference testing in specialized labora-
tories overseas, which is time-consuming and even more 
expensive.
Conclusion
The results have demonstrated that Raman spectros-
copy performed by the NanoRam® has a high sensitiv-
ity and specificity to identify and discriminate between 
anti-malarial drugs. In future medicine quality surveys, 
a handheld RS, preferably in combination with refer-
ence methods such as HPLC, may become the preferred 
method to assess the quality of large quantities of anti-
malarial drugs throughout the supply chain. Hence, a 
handheld RS can be a valuable tool in the ultimate goal of 
malaria elimination.
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